Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials

BACKGROUND: The COVID-19 pandemic highlights the need for therapies that improve immune function in older adults, including interferon (IFN)-induced antiviral immunity that declines with age. In a previous phase 2a trial, RTB101 (previously known as BEZ235), an oral mechanistic target of rapamycin (...

Descripción completa

Detalles Bibliográficos
Autores principales: Mannick, Joan B, Teo, Grace, Bernardo, Patti, Quinn, Dean, Russell, Kerry, Klickstein, Lloyd, Marshall, William, Shergill, Sarb
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8102040/
https://www.ncbi.nlm.nih.gov/pubmed/33977284
http://dx.doi.org/10.1016/S2666-7568(21)00062-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8102040/
https://www.ncbi.nlm.nih.gov/pubmed/33977284
http://dx.doi.org/10.1016/S2666-7568(21)00062-3

Ejemplares similares